Matthew S. Lawrence, MD, PhD
Adjunct Assistant Professor
President and Chief Scientific Officer RxGen
100 Deepwood Drive
Hamden, CT 06517
New Haven, CT 06520-8016
Phone: (203) 498-9706
- BA, Harvard University
- PhD, Stanford University
- MD, Yale University
- Residency, Massachusetts Eye and Ear Infirmary
Dr. Lawrence is a co-founder of RxGen, a private preclinical research organization that evaluates pharmakokinetics and emerging therapeutics.
Areas of Expertise
- Gene Therapy
Publications of Note
Ward KW, Coon DJ, Magiera D, Bhadresa S, Struharik M, Lawrence MS (2009) Exploration of the African green monkey as a preclinical pharmacokinetic model: oral pharmacokinetic parameters and drug-drug interactions. Xenobiotica. 39(3):266-72.
Ward KW, Coon DJ, Magiera D, Bhadresa S, Nisbett E, Lawrence MS (2008) Exploration of the African green monkey as a preclinical pharmacokinetic model: intravenous pharmacokinetic parameters. Drug Metab Dispos. 36(4):715-20.
Lawrence MS, Miller JW (2004) Ocular tissue permeabilities. Int Ophthalmol Clin. 44(3):53-61.
Dumas TC, McLaughlin JR, Ho DY, Lawrence MS, Sapolsky RM (2000) Gene therapies that enhance hippocampal neuron survival after an excitotoxic insult are not equivalent in their ability to maintain synaptic transmission. Exp Neurol. 166(1):180-9.
Phillips RG, Lawrence MS, Ho DY, Sapolsky RM (2000) Limitations in the neuroprotective potential of gene therapy with Bcl-2. Brain Res. 859(2):202-6.